Literature DB >> 7543521

Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1.

K S Kilgore1, J P Shen, B F Miller, P A Ward, J S Warren.   

Abstract

Although TNF-alpha and several products of the activated complement system (e.g., C3b, iC3b, and C5a) are known to modulate endothelial cell function in vitro, relatively little is known about the potential modulatory role of the membrane attack complex (MAC) in endothelial cell activation. Using an in vitro neutrophil-endothelial adhesion assay and a quantitative whole cell ELISA to measure endothelial E-selectin and intracellular adhesion molecule-1 (ICAM-1) expression, we examined the modulatory role of the MAC in TNF-alpha-induced neutrophil-endothelial cell adhesive interactions. Activation of quiescent human umbilical vein endothelial cells (HUVECs) with TNF-alpha results in a concentration-dependent increase in neutrophil adhesion measured at 4 h. Assembly of sublytic concentrations of the MAC on endothelial cells did not result in changes in neutrophil-HUVEC adhesion measured at 4 h. Activation of HUVECs with TNF-alpha followed by assembly of the MAC resulted in a marked increase in neutrophil binding as compared with that observed in cells treated with TNF-alpha alone. Blocking studies of mAb revealed that in either TNF-alpha-stimulated or TNF-alpha and MAC-activated endothelial cells enhanced neutrophil binding was nearly entirely attributable to E-selectin and ICAM-1. This conclusion was further supported by a whole-cell ELISA, which provided evidence that the MAC augments TNF-alpha-induced up-regulation of both E-selectin and ICAM-1. This study provides data that support the conclusion that the distal complement system (MAC) can enhance TNF-alpha-induced proinflammatory endothelial cell functions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543521

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Complement activation promotes muscle inflammation during modified muscle use.

Authors:  J Frenette; B Cai; J G Tidball
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

2.  Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement.

Authors:  B J Czermak; A B Lentsch; N M Bless; H Schmal; H P Friedl; P A Ward
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

3.  Cardiomyopathy is linked to complement activation.

Authors:  Marina Afanasyeva; Noel R Rose
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 4.  Complement-induced impairment of the innate immune system during sepsis.

Authors:  Eric A Albrecht; Peter A Ward
Journal:  Curr Allergy Asthma Rep       Date:  2004-09       Impact factor: 4.806

5.  NF-kappaB activation during IgG immune complex-induced lung injury: requirements for TNF-alpha and IL-1beta but not complement.

Authors:  A B Lentsch; B J Czermak; N M Bless; P A Ward
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

Review 6.  Clinical immunology.

Authors:  T E Mollnes; M Harboe
Journal:  BMJ       Date:  1996-06-08

7.  Complement-induced Impairment of the Innate Immune System During Sepsis.

Authors:  Eric A Albrecht; Peter A Ward
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

8.  The membrane attack complex (C5b-9) in liver cold ischemia and reperfusion injury.

Authors:  Constantino Fondevila; Xiu-Da Shen; Seiichiro Tsuchihashi; Yoichiro Uchida; Maria Cecilia Freitas; Bibo Ke; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Liver Transpl       Date:  2008-08       Impact factor: 5.799

Review 9.  The role of complement activation in atherosclerosis.

Authors:  Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 10.  New concepts of complement in allorecognition and graft rejection.

Authors:  Barbara A Wasowska; Chih-Yuan Lee; Marc K Halushka; William M Baldwin
Journal:  Cell Immunol       Date:  2007-10-24       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.